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Summary. There is a growing gap in productivity in the biopharmaceutical industry. 
The money spent on developing new drugs has increased substantially, but the hoped-
for dramatic increase in new therapies based on recent revolutions in molecular biology 
and genetics has yet to materialize. Long approval times, high-failures rates, and high-
competition account in part for this situation. Some argue that entrepreneurs are not 
promoting fundamental, new discoveries and instead are simply profiting from the 
knowledge generated by academia. In fact, publicly funded research is driving progress 
in a completely new field and the development of a completely new landscape of medi-
cine. The knowledge thereby acquired has dramatically changed the approach to targe-
ting disease. In response, a new model is needed, one that addresses how investment 
in innovation is driven, but also how innovation is done. [Contrib Sci 10:29-34 (2014)]
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Pharmaceutical innovation
Human progress has two interlinked components: innovation, 
i.e., creation, invention, and discovery, and diffusion, i.e., the 
dissemination and uptake of knowledge. In the realm of hu-
man healthcare and drug discovery, innovative products can 
be defined as those that cure or prevent a disease or conditi-
on, decrease mortality or morbidity, decrease the cost of care, 
improve the quality of life, are safer or easier to use, or impro-
ve patient compliance and persistence.
In recent years, there has been a decrease in the number of 
molecular entities or biological license applications that have 
been approved. In the USA, 2012 was a surprisingly “productive” 
year compared to the past two decades, with 33 new molecular 
entities (NMEs) and 6 biologic license applications (BLAs) appro-
ved by the US Food and Drug Administration’s (FDA) Center for 
Drug Evaluation and Research (CDER). The annual average is 30 
FDA approvals, but there are years with as few as 18 [8]. 
Nonetheless, during those same years investment in the se-
arch of new drugs increased. Nowadays, the cost of developing 
new drugs has risen to the point that Francis Collins, the direc-
tor of the National Institutes of Health, described it as a horren-
dous failure: “One point your numbers tell you is how horren-
dous the failure rate is and how that causes the cost of success 
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to be so much higher” [5]. In fact, if we compare the number of 
new drugs approved per dollar spent, the decrease in the for-
mer is indeed alarming. There is a growing gap in productivity in 
the biopharmaceutical industry: money spent on developing 
new drugs has increased substantially, but the hoped-for rapid 
proliferation of new therapies based on recent revolutions in 
molecular biology and genetics has yet to materialize.
Why is this? In the USA, one important reason is that the 
FDA’s approval process, driven by extreme caution, is extre-
mely long. The amount of time from the ‘eureka’ moment of 
discovering a drug candidate to its final approval by the FDA 
can take 10 to 15 years, with an average cost of US$ 1.32 bi-
llion per drug [9]. Assuming that a new effective drug could 
save approximately 10,000 lives, a 10-year wait for its appro-
val means that 100,000 people will die in the meantime. 
Huge investments without success also point to another 
problem. In addition to high failure rates, the failures norma-
lly come at the very end of the process: 40 % in phase III of 
clinical trials, with two-thirds of the failures due to lack of 
efficacy [15]. For some drugs, for example those targeting 
components of the central nervous system, this is extremely 
important because failures at the late phase of a clinical trial 
greatly increase the cost of an ultimately successful drug. In 
addition, once this drug is approved, the market abounds 
with companies competing to sell it, analogous to “too many 
cooks spoiling the broth.” This results in a very high expendi-
tures on promotion and related activities. In the USA—the 
only country for which data on expenditures on all major 
marketing and sales activities are available—total real spen-
ding on pharmaceutical promotions rose from US$ 11.4 billi-
on in 1996 to US$ 29.9 billion in 2005 [11]. Another study 
suggests that the true figure (including meetings and e-pro-
motions) is closer to US$ 57.5 billion [12]. Also in the USA, 
the number of sales representatives is three times the num-
ber of clinicians. This means that physicians receive three to 
four visits per week. 
The January 2013 issue of The Economist contained an 
article with the title ‘Has the ideas machine broke down?’ 
The argument was that entrepreneurs are not leading new, 
fundamental discoveries but are simply profiting from 
knowledge coming from academia, from publicly funded re-
search: “Almost no entrepreneurs discover things fundamen-
tally new, at least while working on their own nickel. Rather, 
in the words of Isaac Newton, they stood on the shoulders of 
giants. In this case, the giants were those scientists and engi-
neers funded by society, through tax payer largess, that crea-
ted the building blocks that led to many of the technological 
breakthroughs we have today.”
The new science of personalized medi-
cine and the genomic era
Publicly funded research has powered a completely new field 
of medicine, with a completely new landscape. This knowledge 
has radically changed the strategies for targeting diseases. 
Some examples of this new landscape are genomic medicine, 
the ENCODE project, synthetic biology, and robotics.
Genomic medicine. Genomic medicine has provided an 
abundance of information about the genetic basis of disease, 
thus providing insight into the physiopathology of disease 
and identifying new therapeutic targets. 
This knowledge is driving a major change in how medici-
ne is perceived; a revolution is underway, based on persona-
lized genomics and direct-to-consumer genomic services. 
Services such as 23andMe, a private DNA testing company, 
will analyze your saliva sample and, a few hours later, will 
send your genotype to your mobile phone, where you can 
share it with your friends on Facebook, perhaps garnering a 
“like.” Although, following ethical concerns, 23andMe no lon-
ger offers health-related services, initially it provided infor-
mation on the risk of developing certain diseases. Additiona-
lly, you can buy access to your ancestry to find out whether 
you are more similar to your mother or your father, and where 
your ancestors came from.
Genomic medicine is driving a new approach to therapy, 
based on a new medical model, personalized medicine. This 
model proposes customizing healthcare via decisions and 
practices tailored to the individual patient, by exploiting gene-
tic and other relevant information. Consider that, for a single 
patient group with the same diagnosis and treated with the 
same medication, there will be responders, non-responders, 
and those who exhibit signs of increased drug toxicity. Perso-
nalized medicine, by tailoring medications based on genetic 
information, will greatly contribute to optimizing treatment.
The ENCODE project. The Encyclopedia of DNA ele-
ments (ENCODE) project is a public research consortium that 
was launched in September 2003 by the US National Human 
Genome Research Institute (NHGRI) to identify all functional 
elements in the human genome [3]. An achievement of EN-
CODE has been the recognition that most of the non-coding 
DNA is involved in the regulation of the expressions of coding 
DNA, with important effects on health. 
Synthetic biology. Another major discovery that is dri-
ving and will drive a change in productivity is the capability of 
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creating new life from inert chemicals. In 2010, Craig Venter 
and his team at the J. Craig Venter Institute reported the cre-
ation of a bacterial chromosome which they used to success-
fully replace the DNA of a bacterium [4]. Similar new entities 
will probably be capable of replicating and of evolving into 
new forms. Craig Venter said: “This is an important step both 
scientifically and philosophically.” We must think about the 
potential uses of future new living organisms. They could be 
used, for example, for producing new drugs. 
Robotics. Brain-computer and body-computer interfaces 
that help people with disabilities to be more independent are 
already available. Computer science has contributed to im-
proving not only the health, but also the social inclusion of 
the disabled, decreasing the cost of dependency. 
Genetics, the environment, and medi-
cine
One of the most important discoveries of recent years is that 
we can shape ourselves, both our brains and our bodies, and 
that these changes can be passed on to the next generation. 
This discovery is based on the recognition that there are chan-
ges in gene activity and expression that are not dependent on 
gene sequence; moreover, they are heritable—but not neces-
sarily. The study of those changes in single genes or sets of 
genes is called epigenetics, and the global analysis of epigene-
tic changes across the entire genome, epigenomics. Epigeno-
mics is one of the fastest emerging scientific fields, promising a 
huge growth potential by revolutionizing the therapeutics and 
diagnostics industries in healthcare. The US NIH Roadmap Epi-
genomics Mapping Consortium was launched as a public re-
source of human epigenetic data to facilitate disease-oriented 
research [http://www.roadmapepigenomics.org/].
Experiments have shown that a puppy that is raised by 
an anxious, low-nurturing mother becomes an anxious 
adult, whereas a puppy that is raised by a relaxed, high-
nurturing mother becomes a relaxed adult. The genome of 
this puppy actually changes, and this change will be trans-
mitted to its progeny. More importantly, we can also change 
the impact of the environment pharmacologically. The 
study of heritable changes in genome function and gene ex-
pression has opened a new gateway in biology, allowing us 
to understand the basis of diseases, and presents incredible 
opportunities for disease diagnosis and drug discovery. The 
epigenomic therapeutic market is expected to explode in 
the coming years. 
The problem, however, is that this basic research is lost in 
translation when it comes to converting findings into real 
therapeutic advances. The substantial increase in investment 
in pharmaceutical research has yielded only slight progress, 
since the new compounds are only marginally better, but 
much more expensive, than existing ones. Moreover, it has 
increased the gap between treatment available to the rich vs. 
the poor. In a survey of physicians, from 2000 to 2010, out of 
approximately 1000 new drugs, only 2 % earned one of their 
top two ratings, corresponding to a real therapeutic advance 
[7]. This is because most of the new drugs are simply the re-
sult of drug repositioning—the application of known drugs 
and compounds to new indications. Drug repositioning has 
grown in importance over the past few years because it is less 
expensive, and the risk versus reward trade-off of the availa-
ble strategies is much better. But it also means that innovati-
on does not reach the market. 
But, what are scientists truly worrying about? The phar-
maceutical industry cannot be the ultimate answer. In fact, 
the effects of the environment must be taken into account. 
The environment is a strong determinant of how we develop 
and function. Genetic susceptibility factors are responsive to 
environmental ones. Genetically-susceptible individuals, 
when subjected to an adverse environment, are much more 
vulnerable and will go on to exhibit, in the case of childhood 
abuse, for example, antisocial behavior [1]. This finding has 
political implications. We are aware that we need to improve 
education, ensure a healthy environment, and change our 
way of interacting with this environment, but such steps 
must be initiated by policy-makers. To quote Leonard Schlain, 
“[T]here is no gene-controlled inheritable trait that cannot be 
altered by the environment […] Humans enter the world as a 
work-in-progress […] Nature/nurture is not an either/or dua-
lity but, rather, represents a both/and type of complementa-
rity.” [4] Gene-environment interactions make people diffe-
rent, and the consequences of these interactions are in many 
cases decisive. 
Given the complexity of how phenotype is determined, 
how powerful or useful will the delineation of an individual’s 
genome be in predicting disease and in choosing therapy? 
Our understanding is far from complete; we need more basic 
science research, and we need more knowledge. Investment 
in science at the moment is below what it should be, and we 
must work to improve this situation. We are fortunate to live 
in a region of the world where science is important. But re-
garding research in medicine, there are other problems. Con-
sider the aims of EU Horizon 2020—the eighth phase of the 
Framework Programs of Research and Technological Deve-
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lopment, the main targets of which are aging and obesity. In 
other words, funding from public agencies is mostly devoted 
to the diseases of developed countries. 
Innovation-distorting economical in-
equalities
Focused innovation is distorted by huge economic inequaliti-
es, which steer innovators away from seeking treatment of 
those diseases predominantly affecting the poor. The pro-
blem is that the map of some disorders, such as malaria, co-
incides with the map of poverty, but is in direct opposition 
with the map of drug and pharmaceutical investment. More-
over, if we compare these maps against the map of corrupti-
on, we see that even if the drugs reach these countries, it 
cannot be taken for granted that they will reach the people 
who need them (Fig. 1). In the words of Huguette Labelle, 
Chair of Transparency International, a non-governmental orga-
nization that monitors and publicizes corporate and political 
corruption, “we must ensure that there are consequences to 
corruption. ‘No to impunity’ cannot just be a slogan—it must 
be carried out with all our combined strength and inspire citi-
zens to speak up and no longer tolerate corruption.” [14]. 
In Spain, there is also a “map of shame.” Government po-
licies of austerity, together with punitive changes to the be-
nefit system, as well as media and ministerial attacks on the 
claimants, to name just a few [2], are placing an increasing 
number of people at risk of poverty and social exclusion. 
While this affects the entire population, the consequences 
are particularly dire for the young population, the future of 
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Fig. 1. (A) Estimate of world poverty (2013). CIA Poverty Stats. Source: Wikimedia Commons. (B) World map 
index of the perception of corruption (2012). The Corruption Perception Index ranks countries and territori-
es based on how corrupt their public sector is perceived to be, using a scale of 0–100, where 0 means that 
a country is perceived as being highly corrupt and 100 that it is perceived as being very clean. Source: Trans-
parency International.
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the country. We could appeal to ethical values, to morality. 
But from neuroscience we know that power (of any kind) 
equals reduced morality. There are studies showing that 
higher levels of power, or wealthier economies, drive more 
unethical attitudes and behaviors [10]. Policy proposals with 
ethical implications or that aim to achieve the egalitarian dis-
tribution of benefits and costs may fail. 
You could argue that we live in a democracy, but from 
neuroscience we also know that there are no rational voters. 
The political brain is an emotional brain and people are dri-
ven by emotions. Politicians use marketing techniques aimed 
at holding their traditional voters as well as widening their 
appeal. But in designing their campaigns they should take 
into account voters’ attitudes, by studying how voters’ elec-
toral memory, sense of responsibility, and emotional state 
are associated with their votes. What do citizens think about 
when they stand in the polling booths? What is the impact of 
electoral arrangements on voting and voters’ perceptions of 
elections? How do voters evaluate government performan-
ce? Answers to these questions would help to generate more 
coherent systems. 
Concluding remarks
The health systems of most countries perform very poorly in 
terms of cost-effectiveness, which reduces their societal va-
lue. Overall efficiency is greatly diminished by lobbying and 
deal-making, the patent application process, litigation, was-
teful marketing, counterfeiting, and deadweight losses. Ad-
verse disturbances of drug development by the scientific or 
regulatory environment have detrimental effects on social 
value. Disruptions in the flow of funding from sales to R&D 
lead to lower social returns. We need to address not only the 
drivers of investment in innovation, but also how innovation 
is done. I would like to see more research of these issues and 
a change in the regulatory environment aimed at raising the 
social value of innovation. 
We need to change the model. The outcome of treatment 
should be included in an assessment of its value. In other 
words, payment for pharmaceuticals should be based on 
performance. We should also improve science funding. And 
finally, academic knowledge, both theoretical and methodo-
logical, should be applied to policymaking. In the words of 
sustainability expert Gareth Kane, “[t]he true barrier to sus-
tainability is about six inches wide—the space between our 
ears. Most of the problems and the solutions can be found 
there” [6]. 
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Resum. Existeix una creixent llacuna en la productivitat de la indústria biofarmacèutica: els 
diners gastats en el desenvolupament de nous fàrmacs ha augmentat molt, però el gran aug-
ment esperat de noves teràpies basades en les revolucions recents de la biologia molecular i 
la genètica encara no s’han materialitzat. El llarg temps d’aprovació de nous fàrmacs, l'alt 
índex de fracassos, i l’alt nivell de competència són algunes de les raons d’aquesta situació. Hi 
ha qui sosté que els empresaris no estan promovent nous descobriments fonamentals i sen-
zillament es beneficien del coneixement que es genera al món acadèmic. De fet, la investiga-
ció finançada amb fons públics està liderant un camp completament nou i el desenvolupa-
ment d’un nou escenari per a la medicina. El coneixement adquirit ha canviat enormement la 
nostra manera d’encarar les malalties. Com a resposta a aquest canvi, cal un nou model que 
tingui en compte com s’inverteix en innovació, i també com es fa la innovació. 
Paraules clau: innovació · indústria farmacèutica · medicina genòmica · epigenètica · 
sistema sanitari 
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